Cancer Health Treatment Update It's Never Too Late to Quit Smoking, Study Shows Quitting even within two years before a lung cancer diagnosis improves survival, researchers report ahead of the virtual ASCO Annual Meeting. FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer Retevmo, the first drug in its class, shrank tumors in over two thirds of previously treated patients. Many Cancer Survivors Stay in Jobs for the Health Insurance This phenomenon, known as job lock, it can also affect the partners of people with cancer. Early Research Finds CBD May Help Combat Brain Cancer Researchers studying dog and human cell cultures found cannabidiol was effective at combating glioblastoma. For all of Cancer Health's coverage of the novel coronavirus and COVID-19, click here. Survey: Half of Cancer Researchers Report Their Work is on Hold It is clear that the COVID-19 pandemic is having a major impact on cancer research, American Cancer Society survey finds. Fear Of Coronavirus Propels Some Smokers To Quit Some studies suggest that smokers who develop COVID-19 are more likely to need intensive treatment. Cancer Health Spring 2020 Check out our new print edition! Advertisement Newsfeed It's Never Too Late to Quit Smoking, Study Shows Colorectal Cancer Program Improves Screening Uptake in Minorities Is Back Pain a Sign of Kidney Cancer? Rates of Testicular Cancer are Rising Among Racial/Ethnic Minorities Blog: Food and Drug Administration (FDA) FDA Approves Lynparza Plus Bevacizumab for Ovarian Cancer Maintenance Treatment FDA Approves Injectable Formulation of Darzalex for Multiple Myeloma FDA Approves Zejula For First-Line Maintenance of Advanced Ovarian Cancer FDA Approves Imbruvica Plus Rituxan for Chronic Lymphocytic Leukemia Newsfeed It's Never Too Late to Quit Smoking, Study Shows Colorectal Cancer Program Improves Screening Uptake in Minorities Is Back Pain a Sign of Kidney Cancer? Rates of Testicular Cancer are Rising Among Racial/Ethnic Minorities Blog: Food and Drug Administration (FDA) FDA Approves Lynparza Plus Bevacizumab for Ovarian Cancer Maintenance Treatment FDA Approves Injectable Formulation of Darzalex for Multiple Myeloma FDA Approves Zejula For First-Line Maintenance of Advanced Ovarian Cancer FDA Approves Imbruvica Plus Rituxan for Chronic Lymphocytic Leukemia

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@cancerhealth.com. Please remember to add update@cancerhealth.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: